Why everyone needs glasses these days (it isn't just screens)
Parents hold a ton of the blame in the rising levels of nearsightedness in children. We can all do more to protect our vision ...
Dr. Stewart from KCU Shares the Dangers of Small Screens on Developing Eyes
KCU Assistant Professor of Primary Care details the trends in nearsightedness in young children. Topic: Screen Time and ...
Shortsightedness is on the rise in children. There’s more we can do than limit screen time
There is evidence more time outside can help slow the progression of shortsightedness in children, due to the role sunlight ...
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...
Manila Bulletin3d
10-hour sleep time: China announces new measures to prevent myopia among children
The Chinese government has unveiled new measures to prevent and curb the rate of myopia among children, as nearsightedness ...
Eye exercises to improve sight – is there any science behind them? An ophthalmologist explains why you shouldn’t buy the hype
You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – ...
Kaleido Scope7d
New UAB clinical trial explores an innovative method to slow nearsightedness in children
Safal Khanal will use the grant to lead a clinical trial to investigate the efficacy of a new myopia treatment option.
pna13d
PBBM sets 2nd week of Oct as Nat’l Myopia Consciousness Week
President Ferdinand R. Marcos Jr. has declared the second week of October as “National Myopia Consciousness Week” in an ...
Eyenovia Shares Plumb New Depths After Study Failure
Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options ...
Eyenovia Mulls Options After Phase 3 Study Failure
The ophthalmic technology company said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform as a potential treatment for pediatric ...